Comparative Pharmacology
Head-to-head clinical analysis: ADAGEN versus LAMZEDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ADAGEN versus LAMZEDE.
ADAGEN vs LAMZEDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ADAGEN (pegademase bovine) is a modified form of the enzyme adenosine deaminase (ADA). It catalyzes the deamination of adenosine and 2'-deoxyadenosine to inosine and 2'-deoxyinosine, respectively, thereby reducing the accumulation of toxic metabolites (deoxyadenosine triphosphate) that cause lymphotoxicity in patients with severe combined immunodeficiency disease (SCID) due to ADA deficiency.
Recombinant human iduronate-2-sulfatase (idursulfase) replaces deficient or absent iduronate-2-sulfatase enzyme, which hydrolyzes the 2-sulfate groups from the heparan sulfate and dermatan sulfate GAGs, preventing their accumulation in lysosomes.
30 U/kg intramuscularly or subcutaneously once weekly; adjust dose based on adenosine deaminase (ADA) activity and clinical response.
Intravenous infusion: 1 mg/kg once weekly.
None Documented
None Documented
Terminal elimination half-life is approximately 3-6 days (mean ~3.5 days) in patients with ADA-SCID, allowing for weekly intramuscular dosing.
Terminal elimination half-life is approximately 100-120 hours. This long half-life supports weekly dosing and maintains therapeutic concentrations throughout the dosing interval.
Renal: approximately 40-60% of administered dose as intact polyethylene glycol conjugate; the remainder undergoes enzymatic degradation or biliary excretion. Fecal elimination is minimal.
Primarily hepatic metabolism; less than 1% excreted unchanged in urine. Biliary/fecal elimination accounts for >90% of the administered dose.
Category C
Category C
Enzyme Replacement
Enzyme Replacement